Sensorion Announces Three Presentations at IEB 2019 in Padua
- An oral presentation in the session "Beyond the Device: New Therapeutic Approaches for Hearing Loss" on SENS-401
- Two preclinical posters on ototoxicity
MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, has contributed three presentations at the 56th Workshop on Inner Ear Biology (IEB 2019) held in Padua, the 7-10th of September, 2019.
In the satellite symposium “Beyond the Device: New Therapeutic Approaches for Hearing Loss” organized and sponsored by our partner Cochlear, the talk entitled “The journey from preclinical to the clinic” reviewed the development of the clinical stage oral otoprotectant SENS-401(Arazasetron), including evidence supporting otoprotective efficacy in preclinical models of severe acoustic trauma and cisplatin-induced ototoxicity.
Sensorion also presented two preclinical studies evaluating the dose-dependence of ototoxicity for the clinically used drugs cisplatin and tobramycin in animal models for pharmaceutical development using Auditory Brainstem Response (ABR) and Distortion Product Otoacoustic Emission (DPOAE) functional measures of hearing loss.
SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment. A small molecule that can be taken orally or via an injection, SENS-401 has received Orphan Drug Designation in Europe for the treatment of sudden sensorineural hearing loss, and Orphan Drug Designation from the US FDA for the prevention of platinum-induced ototoxicity in pediatric population. it has received Investigational New Drug (IND) in June 2019 clearance from the US Food and Drug Administration (FDA) to proceed with Phase 2 clinical trial
Sensorion is a pioneering clinical-stage biopharmaceutical company, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, vertigo and tinnitus. Our clinical-stage portfolio includes two phase 2 products: Seliforant (SENS-111) under investigation for acute unilateral vestibulopathy and Arazasetron (SENS-401) for sudden sensorineural hearing loss (SSNHL). We have built a unique R&D technology platform to expand our understanding of the physiopathology and etiology of inner ear related diseases enabling us to select the best targets and modalities for drug candidates. We also identify biomarkers to improve diagnosis and treatment of these underserved illnesses. Sensorion is launching in the second half of 2019 two preclinical gene programs aiming to correct hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. We are uniquely placed through our platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet need in medicine today.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the ‘Document de référence’ registration document filed with the ‘Autorité des Marchés Financiers’ (AMF French Financial Market Authority) on September 7th, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.